A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine
Completed · Phase 3 · NCT04686136
Conditions: Episodic Migraine, Chronic Migraine
At a glance
- Research payments reported, 2025
- $52,200
- U.S. investigators named
- 23
- Sites paid
- 28
- Planned or actual enrollment
- 596
About the trial
- Sponsor
- AbbVie
- Tested
- Atogepant 60 mg (drug)
- Dates
- Started 2021-02-19; completion 2025-10-20
- Results posted
- Not yet
This study will evaluate the Long-Term Safety and Tolerability of Atogepant 60 mg daily for the Prevention of Migraine in Participants with Chronic or Episodic Migraine
From ClinicalTrials.gov, last updated 2025-12-18. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $52,200 in research payments for this study in 2025 (45 payments).
Products named: Qulipta
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Kerry Knievel, D.O. Neurology · Phoenix, AZ
- Sherry Soefje, M.D. Psychiatry · Oceanside, CA
- Paul K. Brownstone, M.D. Clinical Pharmacology · Boulder, CO
- Deborah A. Burke, MD Neurology · Tampa, FL
- Shital-hiten J. Upadhyay, MD Emergency Medicine · St Petersburg, FL
- Kristi K. George, MD Neurology · Indianapolis, IN
- Andrea L. Haller, MD Neurology · Fort Wayne, IN
- Haydn M. Thomas, M.D. Psychiatry · Prairie Village, KS
- Ahmet F. Dirican, MD Geriatric Medicine · New Bedford, MA
- Dima Hnoosh, M.D. Geriatric Medicine · Baltimore, MD
- Gary D. Berman, M.D. Allergy & Immunology · Minneapolis, MN
- Marshall C. Freeman, MD Neurology · Greensboro, NC
- Thomas A. Wolf, MD Family Medicine · Fremont, NE
- Satkirin Khalsa Family Medicine · Albuquerque, NM
- Sait Ashina, MD Neurology · New York, NY
- Lora J. Mcgill, M.D. Neurology · Memphis, TN
- Donald J. Garcia JR., MD Psychiatry · Austin, TX
- Steven P. Herzog, M.D. Neurology · Dallas, TX
- Murtaza Mussaji, DO Internal Medicine · Houston, TX
- Shane G. Christensen, M.D. OB-GYN (Obstetrics & Gynecology) · Salt Lake City, UT
- Stephen F. Richardson, M.D. Research Study Specialist · Sandy, UT
- Patrick J. Hogan III, D.O. Neurology · Tacoma, WA
- Arifulla -. Khan, MD Psychiatry · Bellevue, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Beth Israel Deaconess Medical Center, MA $13,624
- Cognitive Clinical Trials LLC $7,972
- Linq Research LLC $6,274
- Collective Medical Research LLC $4,000
- Northwest Clinical Research Ctr $3,500
- Allied Physicians Inc $2,750
- Headlands Horizons LLC $2,360
- J Lewis Research Inc $2,000
- Excell Research Inc $1,320
- Josephson Wallack Munshower Neur $1,075
- Clinical Resarch Institute Inc $1,000
- Alpine Clinical Research Center Inc $850
- Albuquerque Clinical Trials Inc $600
- Texas Neurology PA $550
- Highland Clinic Research $500
- Puget Sound Neurology and Integrative Headache Center $500
- Elligo Health Research Inc $400
- Clinical Neuroscience Solutions Inc $400
- Northwest Clinical Research Center $400
- Austin Clinical Trial PArtners $400
- Avail Clinical Research LLC $400
- Collective Medical Research $300
- Headache Wellness Center $250
- Sandhill Research LLC $200
- Alpine Clinical Research Center $200
- Clinical Research Institute $150
- Jwm Neurology $150
- St Josephs Hospital and Medical Center, AZ $75
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.